Loading
A phase 1/2 trial of Test Product HY07121 in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.
Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06639256 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 258 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-05. Interventions recorded: Test Product HY07121.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/